

2024 Annual Results

March 26, 2025




| CONTENTS

| . • Business review

|| . • Growth strategy

|||. • Financial performance



PART ONE

Business review




01 Stable revenue with profits steadily growing

- Revenue reached RMB13.09bn, down by 1.1% YOY, basically stable from the previous year
- Net profit attributable to parent at RMB2.07bn, up by 4.2% YoY after excluding the impact of one-time income in 2023

02 Steadily expanding market share

- **Care consumables:** Capturing the opportunity of VBP with the sales of key products growing steadily at 5%-15%
- **Orthopaedics:** the sales of spine, joint, trauma product lines maintained high growth. Sales of sports medicine and artificial bone products doubled
- **Pharma packaging:** Prefilled drug delivery systems syringes grew by over 20% with the sales of pen injectors starting to ramp up



03 Diversified innovative R&D achievements

- R&D expenses of RMB630mn in 2024, 150 new product registration certificates and 127 patents granted in 2024.
- Key product R&D has achieved key milestones with LONG series anesthesia machine certified and marketed; Anesthesia-related consumables are expected to ramp up in sales with the total anesthesiology solution expected to be launched quickly
- New business areas such as pen injectors, sports medicine, MISS, artificial bone, and skeletal muscle issue repair have developed rapidly, creating new growth curves

Improved shareholder returns 04

- The annual dividend ratio is proposed to increase to 50% in 2024 with the total cumulative dividend paid exceeding RMB7bn since listing
- Share buybacks to demonstrate our confidence in growth and better returns to shareholders






Cost cutting strategy 05

- Promote automation transformation, improve production efficiency and reduce labor costs
- Core products: Give full play to the advantages of mass manufacturing and constantly enhance manufacturing capacity; Non-core products: Control fixed cost expenses
- Import substitution of key parts and materials; Collaborate with suppliers to optimize the supply chain

Further International expansion efforts 06

- We have constantly expand globally with initial achievement of overseas market presence
- We achieved overseas revenue of RMB3.29bn in 2024 with stable percentage of overseas revenue strong overseas trade growth
- Actively promote the integration capabilities of overseas platforms such as Argon, Rad Source and GHC to accelerate the release of synergies

Segment review


| | | Revenue FY24 %YoY | As % of revenue | As % of profit | |
|--|--------------------------------|---|--------------------|----------------|-------|
|  | Medical device | <ul style="list-style-type: none"> ❖ Segment revenue of RMB6.51bn, down by 6.5% YoY with operating profit of RMB1.07bn, up by 1.2% YoY. The sales of key products grew by 5-15% with expanding market share ❖ Constantly improve the product portfolio and expand into new business segments, including perioperative products, urology, endocrinology and endoscopy | -6.5% | 49.8% | 38.7% |
|  | Orthopaedics | <ul style="list-style-type: none"> ❖ Segment revenue of RMB1.44bn, up by 13.2% YoY, and operating profit of RMB220mn, up by 195.9% YoY, with the growth ushering in an inflection point ❖ The sales volume of spine, joint and other key products up by +20% and trauma products up by +10%, with artificial bones and sports medicine making breakthrough progress. | 13.2% | 11.0% | 7.9% |
|  | Pharma packaging | <ul style="list-style-type: none"> ❖ Segment revenue of RMB2.28bn, up by 12.6% YoY, with operating profit of RMB890mn, up by 10.0% YoY ❖ New products like pen injectors under the automatic drug delivery systems began to ramp up in volume in the partnerships with nearly 40 customers at various R&D stages | 12.6% | 17.4% | 32.4% |
|  | Interventional products | <ul style="list-style-type: none"> ❖ Segment revenue of RMB1.98bn, up by 2.5% YoY, with operating profit of RMB440mn¹, down by 5.4% YoY ❖ The revenue from US market up by 5.1%, and that of custom products up by 8.2%; Continue to improve the supply chain, focusing on developing potential markets such as Europe and China | 2.5% | 15.1% | 18.2% |
|  | Blood management | <ul style="list-style-type: none"> ❖ Segment revenue of RMB880mn, down by 15.8% YoY, with operating profit of RMB80mn², down by 41.4% YoY ❖ Revenue dropped slightly for consumables like blood bags due to the decline in domestic blood collection; Rad Source Tech's revenue & profit were affected in the short term by the cyclical effect of key blood irradiator markets and large initial investments in R&D pipelines | -15.8% | 6.7% | 2.8% |

Note: 1. The "operating profit" of the interventional devices segment does not take into account the amortization of intangible assets, depreciation of fixed assets and interest expenses of the segment to reflect the actual operating situation

2. The "operating profit" of the blood management segment does not consider the amortization of intangible assets of the segment to reflect the actual operating situation

PART TWO

Growth strategy



Long term strategy

- The three business strategies of "platformization", "internationalization" and "digitalization" and the two supporting strategies of "talent" and "innovation" are proposed in consideration of industry policy and changes in competition landscape, clinical needs and our resources accumulated

Strategy



Platformization - leveraging the advantages of an open, inclusive and shared platform

- ❖ Build a diversified product ecology and scale operations
- ❖ Meet or exceed customer needs with complete product solutions



Internationalization - Maintain the leading position in China and achieve coordinated growth at home and abroad

- ❖ Ride on industry trends through strategic investment and market licensing
- ❖ The product portfolio go global in a coordinated way, focusing on high-growth overseas markets



Digitalization - Improve operational efficiency and develop digital products

- ❖ Enhance the level of digital management and enhance the competitiveness
- ❖ For specific scenarios, extend hospital management service needs and develop digital products



Talent - Establish talent incentive system

- ❖ Extensively recruit professional and technical talents
- ❖ Continuously optimize the talent incentive system to stimulate employees' creativity



Innovation - Improve the ability to innovate and achieve sustained growth

- ❖ Product intelligent manufacturing iteration, functional improvement, new material empowerment & lean cost control
- ❖ Introduction of professional R&D personnel to tackle key issues

Key strategic initiatives in 2024

➤ Platformization:

- The product lines are expanded and growth more diversified with LONG series anesthesia machine certified and marketed, sports medicine and artificial bone products rolled out rapidly, automatic safety drug delivery systems starting to ramp up in sales volume, cleaner vac systems for thrombus removal launched to market
- The first sales platform is launched as pilot to achieve resource sharing and improve customer satisfaction via channel integration

➤ Internationalization:

- We have achieved initial success in overseas expansion for our product lines via strategic partnership with large overseas players and the expanding agency base
- Academic exchanges and market development have been steadily promoted while the establishment of overseas factories has been actively promoted

➤ Digitization:

- Promote the construction and application of data cockpit and energy management platform to improve the efficiency and quality of operation management
- Launched multi-scene professional management information system products for hospitals to build smart hospitals

➤ Talent:


- Recruit professionals in the areas of R&D, management and sales
- Constantly optimize the talent training system, and provide employees with diversified learning and development opportunities through the Five Star Talent development program

➤ Innovation:

- Continue to increase R&D investment with R&D expenses/sales ratio rising to 4.8%, 127 new patents granted and 150 registration certificates.
- Transfer R&D achievements, establish clinical research bases, and build R&D platforms for institutions and enterprises; Build provincial-level key laboratories and introduce industry leading talents

Platformization strategy - Second growth curve


Nine product series, focusing on 100bn-sized market and creating the second growth curve



Platformization strategy - Second growth curve

Perioperative

- With anesthesiology operating room as the application scenario, perioperative products in the two directions of equipment and consumables to provide customers with professional total solutions
- Equipment products with the goal of “offerings products no one else can or better ones than others” to create high-quality and affordable products through innovation, mainly including anesthesia system, monitoring system, infusion system, hospital ventilator, ultrasound, endoscope series products
- Consumables products: By benchmarking domestic manufacturers, complete product lines, iterate existing products and develop key products in a differentiated way with full product coverage, including airway management, anesthesia & equipment assistance, and pain management
- The first self-developed anesthesia machine has been certified and marketed with the German Red Dot design award. Compared to the models in the same price range, Weigao anesthesia machines offer higher parameters, more standard configurations and greater advantage in price with nearly 2,000 surgical procedures implemented in total with excellent clinical feedback



Key products in 2024



Our first self-developed anesthesia machine certified & marketed



4K endoscopic camera system certified & marketed

(Selected) R&D pipelines



Monitor



Infusion pump



Ultrasonic product




Ventilator


Platformization strategy - Second growth curve

Infusion

- Catering to clinical needs, expand the "light-sensitive", "ultrasonic positioning + ECG" features on the basis of "one tube throughout" (a catheter to meet the infusion needs of patients throughout the treatment process) to further strengthen our dominant position in the infusion products with 15 new products to market over the next three years



Infusion port (>1 year)




全植入式输液港
PORT





PIVC (3-4 days)



Mini midline catheters (1-4 weeks)




Ultrasound catheter tip localization




Axillary vein
Midline catheter tip
中线导管
Middle Line



CVC (1-4 weeks)




中心静脉导管
CVC




PICC

(1-12 months)



经外周穿刺
中心静脉导管
PICC



Midline catheter(1-4 weeks)

Platformization strategy - Second growth curve


Endocrine products & Urinary products & digital products for clinical care

- In the field of **endocrinology**, Weigao strives to become the first-tier players in China in 5 years through technical cooperation with leading player in the industry with BGM products as the core and strategic expansion into the field of CGM system products. We have also achieved milestones in R&D of chronic disease management product series in respect of uric acid, ketone, lipid and blood pressure
- In the field of **urology**, Wego has developed 15 core products in three categories with certified products including ureteral stents, ureteral guidance sheathing, urinary guide wire, percutaneous nephrostomy catheter and accessories, and urinary incontinence suspension belt; R&D pipelines including prostate drug carrying balloon, hot steam ablation system, medical laser equipment, prostate suspension, ureteral metal stent and ureteral balloon catheter.
- In terms of **clinical digital products**, we will create clinical nursing digital products with both hardware and software based on our comprehensive and profound understanding of clinical management to help hospital information rating, consolidate the digital platform base; create a multi-scene digital medical ecology, including smart management (material solutions), smart medical care (nursing, wards, imaging, nephrology, etc.) and smart services (medical solutions)

Endocrinology



Blood glucose, ketone, uric acid & lipid monitor



CGM (pipeline)

Urinary



Ureteral guidance sheathing



Urinary incontinence suspension belt

Clinical digital products



Smart ward - vital signs detection system

Platformization strategy - Second growth curve

Orthopaedics & Pharma packaging & Interventional & Blood Management

- In the field of **orthopaedics**, we have rapidly established our presence in sports medicine, artificial bone, PRP and MISS fields with series of products enjoy great market potential, which will become a new growth curve going forward
- In the field of **pharma packaging**, new products like pen injectors under the automatic drug delivery systems began to ramp up in volume in the partnerships with nearly 30 customers at various R&D stages, creating a benchmark for partnership in GLP-1 and autoimmunity fields, taking the lead in the field; Iteratively develop disposable multi-dose pen syringes to meet customers' diversified product needs
- In the field of **interventional products**, we continue to develop new products, penetrate into the VTE market and increase shares in the DVT and PE market through our CLEANER VAC system
- In the field of **blood management**, we continue to promote the R&D and marketing of cryoprecipitate preparation equipment, the second generation of platelet apheresis machines and consumables, and methylene blue pathogen inactivation consumables; Continue to leverage Rad Source brand and technical strengths to diversify and expand products, and actively promote research and development and results transformation in fields such as non-destructive testing, biology and scientific research

Orthopaedics



Absorbable interface screw

PRP

Pharma packaging



Gen2 Pen injector (pipeline)

Interventional products



CLEANER VAC system

Blood management



Platelet apheresis machine (pipeline)

Platformization strategy - in-depth expansion

- Continue to promote the integration of sales channels with the first pilot sales platform launched, focus marketing resources on the development and maintenance of core customers, improve the product penetration of KAs (esp. tertiary hospitals) and improve the contribution of individual customers
- Continue to develop new markets, seize the major opportunities of volume procurement, and rapidly increase the coverage of county-level hospitals; Increase the number of prefecture-level offices and strengthen customer services for hospitals at and below the county level



Number of customers (as of December 31, 2024)

| | New customers | Domestic customers total | Overseas total |
|---------------------------|----------------------|---------------------------------|-----------------------|
| Hospital | 196 | 3,998 | 3,290 |
| Blood station | 0 | 419 | - |
| Other medical institution | 26 | 1,204 | 2,053 |
| Distributor | 174 | 4,545 | 2,342 |
| Total | 396 | 10,166 | 7,685 |

Internationalization strategy - Going global

- Internationalization strategy is our key growth strategy in the medium and long term by strengthening our brand influence overseas through overseas factory establishment, product registration and marketing as well as overseas M&As
- Strategic objectives of global presence:
 - Domestic market: Introduce overseas high-end medical device products and advanced technologies into the Chinese market via strategic investment and market licensing to further improve products and optimize product portfolio.
 - Going global: Accelerate the global presence in the next ten years to transform ourselves from WEGO Manufacturing to WEGO Creation and from cross-border trade to the global brand, and strive to become a global leading player in the medical device industry



Internationalization strategy - business development



Clinical consumables



Orthopaedic consumables



Pharma packaging



Interventional products



Transfusion consumables

| | | | | | |
|----------------------|---|---|---|--|--|
| NA | Cooperation with large procurement companies | Investigation and observation stage | Actively develop top pharma companies as customer | Argon HQs, core market, maintaining competitive advantages | Investigation and observation stage |
| Europe | ODM cooperation | Raise Chinese brand awareness | Reached strategic cooperation with a pharma company | Strengthen market penetration | MDR certification |
| Latin America | Increase target country coverage | Spine, sports medicine businesses achieved milestones in Brazil | Bulk delivery to core pharm companies in SA | Increase target country coverage | The product line covers key markets such as Argentina, Brazil and Colombia |
| Middle East & Africa | Achieve international strategic project cooperation in the One Belt and One Road countries and African market | Host marketing & academic events to raise awareness | Successfully developed pharm companies in North Africa and the Middle East as customers | Market development stage | Become one of key suppliers; Saudi market medical registration |
| SEA | Agency channel development; promote cooperation to build local plants | Completed the confirmation of agency for three key orthopaedic product lines with local distributors, and opened sales branches in Thailand and Indonesia | Become one of key suppliers | Agency channel development | Achieved high growth in Indonesia and Vietnam |

Digital product

- Actively cooperate with medical institutions to explore new smart hospital models and provide better medical services for patients
- Create a multi-scene digital medical ecology, including smart management (material solutions), smart medical care (nursing, wards, imaging, nephrology, etc.) and smart services (medical solutions)
- Service platform for nurses and an online community platform in the field of clinical nursing

Digital production and operation management

- AI application:** Study on the application of AI technology in scenarios like "perioperative anesthesia in-depth closed-loop control" and "intelligent vascular evaluation" with more innovative studies on "intelligent monitoring and early warning system" and "multi-device intelligent linkage" in the pipeline
- Improving intelligent manufacturing:** Continue to promote the digital transformation of production and manufacturing, introduce advanced automation equipment and intelligent management systems, build unmanned plants, and improve production efficiency and product quality
- Digital operation system upgrade:** The application of digital tools such as sales cockpit, management cockpit, energy management platform, and AI business assistant has significantly improved operational efficiency and management



Innovation and talent strategy - R&D driven, recruit talents **WEGO 威高**

WEGO will seize the opportunity to innovate, increase investment in R&D, and continue to attract global talents to accelerate business growth

Existing products iteration

- ✓ Strengthen the iteration and R&D of existing products by product line
- ✓ Existing products upgrade, function improvement, new material application, cost control

Continue increasing R&D investment

- ✓ Total R&D expenditure in 2024 at RMB620mn, up by 5% YoY, with expanding R&D team
- ✓ In 2024, 127 new patents granted in China, 147 pending patent applications, and 150 new product registration certificates obtained. Overseas division with over 749 product registration certificates and 183 patents

Talent recruiting


- ✓ Actively attract all kinds of talent, including senior managers from MNCs
- ✓ Set the second HQs in Shanghai to better leverage location advantages there to attract more and better talents
- ✓ Talents not only help the growth of existing segments, but also help develop more new segments and growth curves

New product development

- ✓ Set up R&D centers in Shanghai and Suzhou to focus on key technology bottlenecks and key product R&D
- ✓ Achieve new product presence via aggressive M&As at home and abroad

Invest in potential new businesses

- ✓ Closely follow industry trends, build presence early on, and increase investment or seek M&As when appropriate to become new business segments





Implement sustainable green development

As the first healthcare "green bond" client in Asia of World Bank's International Finance Corporation (IFC), our sustainable development strategy has been strongly supported and highly recognized by the IFC

- **Green and low-carbon:** Vigorously promote the application of green energy-saving technologies, processes and equipment, and promote the high-end, intelligent and green transformation of the industry. Develop garden-style campus, gardens and roads. Selected as the advanced collective unit of green, low-carbon and high-quality development in Shandong Province
- **Energy conservation and emission reduction:** Adopt the energy management platform for panoramic online monitoring of energy use, analysis and optimization of comprehensive energy consumption through digital management means to achieve lean energy management. Promote the construction of "waste free factories" and achieve the recycling of resources



Fulfil CSR

Our core values of "conscience, sincerity and loyalty" will be implemented into the practice of corporate social responsibilities

- **Assistance in employment of the disabled:** Our subsidiary Weihai Jierui Medical Products is a well-known social welfare enterprise in Shandong, providing employment opportunities for people with disabilities and helping them integrate into society
- **Active participation in social services:** Our "Conch Girl" home care service project was selected as a national rural social service model; Donated health products to families with financial difficulties and elderly care institutions in Weihai City, benefiting over 2,100 infants and 36 elderly care institutions; Assisted Weihai's charity project of serious disease relief, benefiting nearly 200 patients with serious diseases; the "Kindness Day Donation" had a total donation of RMB14 million in 2024.



Improving corporate governance

- **Adhere to compliance management:** Abide by the law, combat corruption and uphold integrity, advocate fair competition
- **Focus on gender equality:** Increase the percentage of women on the board and senior management
- **Sustainable supply chain:** While adhering to our own high standards of business ethics, we seek supply chain partners with the same high ethical standards and quality, strengthen supplier and partner management, and promote common development

PART THREE


Financial performance




Key financials




Revenue^{1, 2}(RMBm)




Overseas sales (RMBm) & percentage³



R&D expenses(RMBm) & Expense ratio



Net profit attributable to shareholders of the Company^{1,2,4,5,6}(RMBm)



Notes:


1. Excluding the impact of income and net profit related to pandemic control supplies; 2. Excluding the impact of accounting restatement under the same control; 3. Restated regions for overseas revenue; 4. Deducted the special item of one-time cost of Argon loan replacement in 2019; 5. Deducted the product liability withholding expense in 2021, the passive dilution income of Weigao Blood Purification Products in 2022, the after-tax income recorded in the recovery of land and housing by the government, and the after-tax cost of product liability claims; 6. Deduction of one-time after-tax income attributable to 2023

The above data are only used to show the trends at our operating level with specific data subject to results disclosure

Segment revenue & operating profit

Revenue breakdown

2024




Segment revenue(RMBm)

| | 2024 | 2023 |
|-------------------------|---------------|---------------|
| Medical devices | 6,512 | 6,961 |
| Pharma packaging | 2,279 | 2,024 |
| Interventional products | 1,980 | 1,931 |
| Orthopaedics | 1,439 | 1,271 |
| Blood management | 877 | 1,042 |
| Total | 13,087 | 13,229 |

Operating profit breakdown

2024



Segment operating profit(RMBm)

| | 2024 ¹ | 2023 ¹ |
|--------------------------------------|-------------------|-------------------|
| Medical devices | 1,067 | 1,054 |
| Pharma packaging | 893 | 812 |
| Orthopaedics | 219 | 74 |
| Interventional products ² | 442 | 467 |
| Blood management ³ | 78 | 133 |
| Total | 2,699 | 2,540 |

Notes:

1. The above data are only used to show the trends at our operating level with specific data subject to results disclosure









2. The "operating profit" of the interventional devices segment does not take into account the amortization of intangible assets and interest expenses of the segment to reflect the actual operating situation

3. The "operating profit" of the blood management segment does not consider the amortization of Rad Source intangible assets to reflect the actual operating situation

Geographical distribution

- The overseas revenue of RMB3.29bn in 2024, 25.1% of total revenue, up by 8.7% YoY, with enhancing overseas competitiveness
- We have achieved initial success in overseas expansion for our product lines via strategic partnership with large overseas players and the expanding agency base
- Set up an office in Singapore to strategically explore the potential of the SEA market and actively push for the establishment of factories overseas

Category revenue (RMBm)


| Region | 2024 | % of total | 2023 | % of total | % YOY Growth |
|------------------------------|--------|--|--------|---|--------------|
| Domestic | 9,800 |  74.9% | 10,204 |  77.1% | -4.0% |
| US | 1,402 |  10.7% | 1,302 |  9.8% | 7.7% |
| Europe, Middle East & Africa | 851 |  6.5% | 710 |  5.4% | 19.9% |
| Asia (ex. China) & others | 1,034 |  7.9% | 1,013 |  7.6% | 2.0% |
| Overseas sub-total | 3,287 |  25.1% | 3,025 |  22.9% | 8.7% |
| Total | 13,087 | | 13,229 | | -1.1% |

Cash flow and Capex

Cash flow and Capex^{1,2}

- Net operating cash flow and free cash flow were stable in 2024
- Stable cash flow performance as operating cash flow increased and capital expenditure stabilized; positive free cash flow for the seventh consecutive year since 2018

Cash flow and CAPEX (RMBm)



Notes:

1. Net of a one-time cash outflow of RMB460 million due to product liability in 2022

2. The effect of accounting restatement of the same control not considered from 2013 to 2023

The above data are only used to show the trends at our operating level with specific data subject to results disclosure

Increased dividend ratio

- The Board of Directors proposed in the second half of 2023 to significantly increase the annual dividend ratio of 2023 to 40% due to strong operating cash flow and free cash flow
- The dividend ratio was maintained at 40% for 1H 2024 and proposed to increase to 50% for the full year of 2024 with the proposed dividend per share at RMB 0.1235 yuan and the total dividend up by 29% YoY
- We actively focus on shareholder returns. The cumulative dividend of nearly RMB7.3bn since listing, far exceeding the amount of equity financing, with CAGR of more than 20%

Total dividend (RMBm)^{2,3}



Notes:

1. The dividend ratio is based on the net profit at the operating level, excluding various one-time non-cash income
2. In the first half of 2010, the Board of Directors recommended the issuance of one bonus share for each existing share held. In the second half of 2010, the Board of Directors recommended the payment of a final dividend of RMB0.075 per share for the year ended 31 December 2010, amounting to RMB160 million, and the actual dividend for the second half of 2010 was RMB320 million
3. The 2024 final dividend is subject to approval by the general meeting of shareholders

Additional Financial data

| | | 2024 | 2023 |
|---------------------------------|--|------------|------------|
| Working capital | Inventory turnover days ¹ | 139 days | 132 days |
| | Accounts receivable turnover days ¹ | 162 days | 152 days |
| | Accounts payable turnover days ¹ | 107 days | 95 days |
| Cash & Liabilities | Bank balance & cash | RMB 7.78bn | RMB 6.99bn |
| | Total debt | RMB 4.19bn | RMB 4.17bn |
| | Net cash | RMB 3.59bn | RMB 2.82bn |
| Leverage analysis | Total debt/EBITDA (x) | 1.1x | 1.2x |
| | Net debt/EBITDA (x) | Net cash | Net cash |
| | Interest coverage ² (x) | 14.7x | 13.0x |
| Current ratio & return analysis | Current ratio | 3.2x | 2.5x |
| | ROE | 8.9% | 9.0% |
| | ROE | 6.3% | 6.1% |

Notes:

1. Represents the average working capital days, and accounts payable turnover days take into account the effect of notes payable

2. Interest coverage = EBITDA / financing costs

The above data are only used to show the trends at our operating level with specific data subject to results disclosure


Non-IFRS financial statement reconciliation

WEGO 威高

| RMB million | 2024 | 2023 | Change |
|--|--------|--------|--------|
| Revenue | 13,087 | 13,229 | -1.1% |
| Net profit attributable to shareholders | 2,067 | 2,002 | 3.2% |
| One-time benefits | | 20 | |
| Adj. profit attributable to shareholders (Net of one-time benefits) | 2,067 | 1,982 | 4.2% |

Company development milestones

WEGO 威高



Disclaimer

This document does not constitute, or form part of any offer for subscription or sale of, or solicitation of any offer to subscribe for or sale of any securities of Shandong Weigao Group Medical Polymer Company Limited ("Weigao Group"), nor shall it be construed as calculated to invite any such offer, nor shall it form the basis of, nor can it be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever.

Forward-Looking Statements

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of Weigao Group, and certain of the plans and objective of the management of Weigao Group. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of Weigao Group to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such forward-looking statements were based on assumptions regarding Weigao Group's present and future business strategies and the political and economic environment in which Weigao Group and its subsidiaries will operate in the future. Reliance should not be placed on these forward-looking statements, which reflect the view of Weigao Group's management as of the date of this presentation only.

The logo for WEGO features the word 'WEGO' in a bold, blue, sans-serif font. The letters are filled with a collage of images showing medical professionals in white coats and blue scrubs working in a clinical setting. To the right of 'WEGO' is the Chinese characters '威高' in a stylized, blue, sans-serif font. The background of the entire image is a light blue, misty landscape with stylized mountains and buildings.

WEGO 威高

偕同白衣使者 开创健康未来

